Plain-English translation of NCT07163273 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to treating advanced pancreatic cancer by alternating between two chemotherapy combinations: and . Instead of using just one treatment, the study hypothesis is that switching back and forth between these two medications each month may work better at controlling the cancer than what doctors have seen with standard approaches.
Advanced pancreatic cancer is very difficult to treat, and current standard chemotherapy has limited effectiveness. This trial exists to see whether alternating between two different medication combinations might improve outcomes for patients who have just been diagnosed with metastatic pancreatic cancer.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy on a monthly alternating schedule: one month you receive (given on days 1 and 15), and the next month you receive gemcitabine plus nab-paclitaxel (given on days 1, 8, and 15). The medications are delivered intravenously at the hospital or clinic. Throughout the trial, you would have regular blood tests, imaging scans, and doctor visits to monitor how well the treatment is working and watch for side effects. The study enrolls 41 patients at Northwell Health.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States